The annual Value Investor Conference is one of the premier events surrounding�Berkshire Hathaway's�annual meeting in Omaha. The Motley Fool's Joe Magyer, Michael Olsen, and Rex Moore were in attendance and talked with several value investors.
In today's video, Joe chats with Wedgewood Partners' David Rolfe about Apple's (NASDAQ: AAPL ) greatest advantage.
Take a bite?
There's no doubt that Apple is at the center of technology's largest revolution ever and that longtime shareholders have been handsomely rewarded, with more than 1,000% gains. However, there is a debate raging as to whether Apple remains a buy. The Motley Fool's senior technology analyst and managing bureau chief, Eric Bleeker, is prepared to fill you in on reasons to buy and reasons to sell Apple and what opportunities are left for the company (and your portfolio) going forward. To get instant access to his latest thinking on Apple, simply click here now.
Top 5 Tech Companies To Watch For 2014: China Electronics Corporation Holdings Co Ltd (85)
China Electronics Corporation Holdings Company Limited is an investment holding company. The Company, through its subsidiaries, is engaged in design, research and development and sale of integrated circuits. The Company�� integrated circuits design business consists of the design of integrated circuits chips and the development of application system. Its products are used in smart cards, such as identity cards, social security cards, telecommunications cards and electric cards. Its products are also applied in wireless local area networks (WLAN). During the year ended December 31, 2011, the Company obtained 17 new patents, and registered another 16 computer software copyrights and 11 integrated circuits layout designs. Its subsidiaries include CEC Integrated Circuit (Beijing) Co., Ltd, CEC Huada Electronic Design Co., Ltd and others.Top 5 Tech Companies To Watch For 2014: Fuel Tech Inc.(FTEK)
Fuel Tech, Inc. uses a suite of advanced technologies to provide boiler optimization, efficiency improvement, and air pollution reduction and control solutions to utility and industrial customers worldwide. It operates through two segments, Air Pollution Control Technologies and FUEL CHEM Technologies. The Air Pollution Control Technologies segment includes technologies, such as low and ultra low NOx Burners, over-fire air systems, NOxOUT and HERT selective non-catalytic reduction systems, and advanced selective catalytic reduction systems to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. This segment distributes its products through direct sales force and agents. The FUEL CHEM Technologies segment uses chemical processes in combination with advanced computational fluid dynamics and chemical kinetics modeling boiler modeling for the control of slagging, fouling, corrosion, opacity, and other sulfur trioxide-r elated issues in furnaces and boilers through the addition of chemicals into the furnace using Targeted In-Furnace Injection technology. This segment?s programs improve the efficiency, reliability, and environmental status of plants operating in the electric utility, industrial, pulp and paper, waste-to-energy, university, and district heating markets; and are installed on combustion units in North America, Europe, China, and India for treating various solid and liquid fuels, including coal, heavy oil, biomass, and municipal waste. It provides operational, financial, and environmental benefits to owners of boilers, furnaces, and other combustion units. The company was founded in 1987 and is headquartered in Warrenville, Illinois.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Fuel-Tech (FTEK), which uses a suite of advanced technologies to provide boiler optimization, efficiency improvement and air pollution reduction and control solutions to utility and industrial customers. This stock is off to a slow start in 2013, with shares up just 7% so far.
If you take a look at the chart for Fuel Tech, you'll notice that this stock has entered a tight consolidation chart pattern over the last month, with shares moving between $4.19 on the downside and $4.78 a share on the upside. Shares of FTEK are now starting to trend higher and move within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in FTEK if it manages to break out above some near-term overhead resistance levels at $4.66 to $4.68 a share and then once it takes out more resistance at $4.78 to its 52-week high at $5.20 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 77,549 shares. If that breakout hits soon, then FTEK will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets of that breakout are $5.50 to $6, or even $7 a share.
Traders can look to buy FTEK off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $4.33 a share, or just below its 200-day at $4.14 a share. One can also buy FTEK off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Heal Care Companies To Watch For 2014: Omnicell Inc.(OMCL)
Omnicell Inc. provides automated solutions for hospital medication and supply management primarily in the United States and Canada. The company offers medication use products, which include OmniRx that automates the management and dispensing of medications at the point of use; SinglePointe, a software product that controls medications on a patient-specific basis; AnywhereRN, a software that allows nurses to remotely operate automated dispensing cabinets; Pandora Analytics, a reporting and data analytics tool; and Savvy Mobile Medication System, a mobile platform for hospital information systems. Its medication use products also include OmniLinkRx, a software product that automates communication between nurses and the pharmacy; WorkflowRx, an automated storage, retrieval, inventory management, and repackaging solution; controlled substance barcode inventory management system; and Anesthesia Workstation, a secure dispensing system for the management of anesthesia supplies an d medications. In addition, the company provides medical and surgical supply products, which comprise Omnicell Supply Solution that automates the management and dispensing of medical and surgical supplies at the point of use; Supply/Rx Combination Solution, which manages medications and supplies in one versatile cabinet; Omnicell Tissue Center that manages the chain of custody for bone and tissue specimens; OptiFlex SS, which supplies modules for the perioperative areas; OptiFlex CL that supplies modules for the cardiac catheterization lab and other procedure areas; and OptiFlex MS, a system for the management of medical and surgical supplies. Further, it provides customer education and training, and maintenance and support services. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Omnicell (Nasdaq: OMCL ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Omnicell (Nasdaq: OMCL ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Omnicell doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 33.5%, and inventory increased 53.7%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue expanded 35.8%, and inventory increased 53.7%. Over the sequential quarterly period, the trend looks OK but not great. Revenue dropped 3.4%, and inventory dropped 2.9%.
Top 5 Tech Companies To Watch For 2014: Labrador Tech Inc (LTX.V)
Labrador Technologies Inc. engaged in the research and development, and marketing of data retrieval technology. The company specializes in Data-Flow Management software, which comprises data-plumbing, data-adaptors, data integration, portal solutions, and on-demand data query and reporting applications that helps software vendors, data vendors, and company developers to deliver data to their target audiences by plugging users in and eliminating the need for manual intervention. It offers eTriever, a WebMap-based generic data browser and query tool that provides comprehensive query, reporting, and exporting capabilities to the oil and gas data sectors; and Model-LAB, a development module, which is used to construct Labrador model files by reverse-engineering existing data models and extracting the metadata. The company�s products also include QueryJoiner that allows business users to query data from two or more different servers at the same time, and combine the data into one MS Excel report; and LABengine, a Labrador engine, which implements a high-level query language that permits application developers to write SQL queries. Labrador Technologies Inc. was founded in 1981 and is headquartered in Calgary, Canada.
Top 5 Tech Companies To Watch For 2014: Exelixis Inc.(EXEL)
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer. It focuses on developing Cabozantinib, an inhibitor of tumor growth, metastasis, and angiogenesis that target MET, VEGFR2, and RET, which are key kinases involved in the development and progression of various cancers. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular cancer, and melanoma. In addition, Exelixis, Inc. involves in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, Genentech, Inc., Boehringer Ingelheim Gm bH, and GlaxoSmithKline and Daiichi Sankyo Company Limited. Its products under development through collaborations include XL475, XL281, XL139, and XL413 inhibitors; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147, XL765, and isoform-selective PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; sphingosine-1-phosphate type 1 receptor; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Sean Williams]
High-risk, high-reward suggestions
Exelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on. - [By Selena Maranjian]
Finally, SAC Capital's biggest closed positions included Coach�and Dover. Other closed positions of interest include Exelixis (NASDAQ: EXEL ) and, also,�Tronox Ltd. (NYSE: TROX ) . Biotech company Exelixis recently reported non-blowout early sales of its thyroid cancer drug, Cometriq. Some are waiting to see if the drug gets approved to treat prostate cancer, too, and the company is looking at treating as many as nine different�conditions with it, such as bone tumors. On the other hand, Cometriq is expensive, and the company's debt has been growing, along with its share count.
No comments:
Post a Comment